Protease Inhibitors in Chronic Hepatitis C: An Update Chapter 4 – Case Study: Treatment Naive Edited by Morris Sherman MD BCh PhD FRCP(C) Associate Professor of Medicine University of Toronto November 2012 Case Study: Treatment Naive Edward Tam MD FRCPC Medical Director LAIR Centre Ms. MH 31 year old female Diagnosed in 2004 with genotype 1a HCV Previous IVDU Otherwise healthy Meds: Milk thistle No Biopsy ALT 1-2 x ULN on serial monitoring Ms. MH Followed periodically with monitoring of liver biochemistry FibroScan December 9, 2010: 4.9 kPa What evidence supports the use of Milk Thistle? Is FibroScan a reliable and accurate tool for fibrosis assessment? Does it represent a viable alternative to liver biopsy? FibroScan versus Liver Biopsy 1.00 Sensitivity 0.75 0.50 AUROC (95% CI) ≥ F2: 0.74 (0.68-0.80) ≥ F3: 0.89 (0.84-0.94) F4: 0.94 (0.90-0.97) 0.25 0.00 0.00 0.25 0.50 0.75 1.00 1-Specificity Myers RP et al. Can J Gastroenterol. 2010 Nov;24(11):661-70 Ms. MH FibroScan December 9, 2010: 4.9 kPa (consistent with stage 0 – 1 fibrosis) Discussions with patient throughout 2011 regarding therapy Although no medical urgency, very keen to pursue therapy for personal reasons Ms. MH January 6, 2012, treatment initiated with pegylated interferon alpha-2b (120mcg) plus ribavirin (500mg BID), as planned lead-in to boceprevir-based treatment. Week 0 HCV RNA 5.29 logs ALT 106 Hb 144 Plts 295 Neutrophils 6.0 Ms. MH: Week 4 Results Week 0 Wk 2 Wk 4 5.29 logs -- Undetectable ALT 106 53 33 Hb 144 120 108 Plts 295 236 214 Neutrophils 6.0 2.0 2.0 HCV RNA Given the undetectable HCV RNA at the end of WK4 lead-in (dual therapy), is adding Boceprevir necessary? Significance of Lead-in Response SPRINT-2: SVR based on degree of early interferon response (log decline in HCV RNA at week 4 of P/R in all patients (cohort 1 + cohort 2) PR48 BOC RGT 100 % of patients with SVR 89 90 90 89 89 89 97 80 79 80 BOC/PR48 70 72 74 65 60 58 60 45 40 33 43 28 28 30 21 20 0 0 5 Log10 viral load decrease after weeks of P/R lead-in Vierling et al. EASL 2011. Results Through Week 12 Wk 4 Wk 6 Wk 8 Wk 10 Wk 12 Undetectable -- Undetectable -- Undetectable ALT 33 27 26 22 28 Hb 108 107 101 91 94 Plts 214 179 177 175 174 Neutrophils 2.0 1.3 1.6 1.2 1.2 HCV RNA Boceprevir added with 5th interferon injection HCV RNA remains undetectable Due to worsening anemia and fatigue, RBV dose reduced to 600mg total daily dose after wk 10 results Results Through Week 24 Wk 12 Wk 16 Wk 20 Wk 24 Undetectable -- -- Undetectable ALT 28 32 25 24 Hb 94 105 101 103 Plts 174 171 164 169 Neutrophils 1.2 1.4 1.0 1.0 HCV RNA HCV RNA remained undetectable through week 24, and patient qualifies for shortened duration therapy (to D/C at week 28) The Canadian Liver Foundation gratefully acknowledges the participating health care professionals for their contributions to this project and for their commitment to the liver health of Canadians. The Canadian Liver Foundation (CLF) was the first organization in the world devoted to providing support for research and education into the causes, diagnoses, prevention and treatment of all liver disease. Through its chapters across the country, the CLF strives to promote liver health, improve public awareness and understanding of liver disease, raise funds for research and provide support to individuals affected by liver disease. For more information visit www.liver.ca or call 1-800-563-5483. This project made possible through the financial support of Merck Canada Inc. The views, information and opinions contained herein are those of the authors and do not necessarily reflect the views and opinions of Merck Canada Inc.